Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 64OTHER 39NIH 8NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 46Magnetic Resonance Spectroscopy 37Cyclophosphamide 28Vincristine 20Radiation 19Dexamethasone 19Cisplatin 18Biopsy 18Radiotherapy 17Etoposide 17Carboplatin 16Cytarabine 13Leucovorin 12daratumumab 11Methotrexate 11durvalumab 10Standard of Care 10Radiotherapy, Intensity-Modulated 10Platinum 10Gemcitabine 10Doxorubicin 10Docetaxel 10Practice Guidelines as Topic 9Calcium Dobesilate 91,2-diaminocyclohexaneplatinum II citrate 9merphos 8dexamethasone acetate 8dexamethasone 21-phosphate 8auricularum 8X-Rays 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Injections × 90 days × Clear all
NCT07085728 2026-05-15

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
74 enrolled
Plasma cell

Multiple Myeloma

NCT04293562 2026-05-05

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Children's Oncology Group

Phase 3 Recruiting
1,186 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡